ATE510536T1 - Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen - Google Patents

Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen

Info

Publication number: ATE510536T1
Authority: AT; Austria
Prior art keywords: treatment; tissue diseases; dihydroxybenzene derivatives; reactive tissue; reactive
Prior art date: 2006-08-16

Application number

AT07788436T

Other languages

English (en)

Inventor

Sanchez Pedro Cuevas

De Tejada Gorman Inigo Saenz

Gallego Guillermo Gimenez

Frutos Javier Angulo

Lapez Luis Ignacio Rivas

Nuncio Francisco Javier Moreno

Jaen Tomas Fernando Fernandez

Puerto Rosa Maria Lozano

Garrido Antonio Romero

Lapez Serafin Valverde

Original Assignee

Action Medicines Sl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-16

Filing date

2007-08-15

Publication date

2011-06-15

2006-08-16 Priority claimed from ES200602217A external-priority patent/ES2315117B1/es

2007-08-15 Application filed by Action Medicines Sl filed Critical Action Medicines Sl

2011-06-15 Application granted granted Critical

2011-06-15 Publication of ATE510536T1 publication Critical patent/ATE510536T1/de

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Neurology (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT07788436T 2006-08-16 2007-08-15 Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen ATE510536T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
ES200602217A ES2315117B1 (es)	2006-08-16	2006-08-16	Uso de derivados 2,5-dihidroxibencenicos en la preparacion de medicamentos utiles en el tratamiento de asma.
ES200701855		2007-07-02
PCT/EP2007/058456 WO2008020042A1 (en)	2006-08-16	2007-08-15	Use of 2, 5-dihydroxybenzene derivatives for the treatment of tissue reactive diseases

Publications (1)

Publication Number	Publication Date
ATE510536T1 true ATE510536T1 (de)	2011-06-15

Family

ID=38515369

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT07788431T ATE509621T1 (de)	2006-08-16	2007-08-15	Verwendung von 2,5-dihydroxybenzolderivaten zur behandlung von arthritis und schmerzen
AT07788436T ATE510536T1 (de)	2006-08-16	2007-08-15	Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT07788431T ATE509621T1 (de)	2006-08-16	2007-08-15	Verwendung von 2,5-dihydroxybenzolderivaten zur behandlung von arthritis und schmerzen

Country Status (8)

Country	Link
US (2)	US20080114063A1 (de)
EP (3)	EP2056804B1 (de)
AR (5)	AR062399A1 (de)
AT (2)	ATE509621T1 (de)
CL (5)	CL2007002392A1 (de)
ES (1)	ES2495965T3 (de)
PT (3)	PT2056805E (de)
WO (5)	WO2008020031A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070149618A1 (en)	2004-02-17	2007-06-28	Action Medicines, S.L.	Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
US20080125485A1 (en)	2004-02-17	2008-05-29	Action Medicines	Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis
ES2238924B1 (es) *	2004-02-17	2006-12-01	Investread Europa, S.L.	Uso del acido 2,5-dihidroxibencenosulfonico, en la fabricacion de medicamentos de aplicacion en el tratamiento de enfermedades angiodependientes.
US20080113947A1 (en)	2006-08-16	2008-05-15	Action Medicines	Use of 2,5-Dihydroxybenzene Compounds and Derivatives for the Treatment of Rosacea
US20110196040A1 (en)	2008-02-15	2011-08-11	Action Medicines S.L.	Skin Penetration Enhancing Systems for Polar Drugs
FR2951085B1 (fr) *	2009-10-09	2012-05-18	Inst Substances Vegetales	Utilisation de composes phenoliques pour la deglycation des proteines
ES2385160B1 (es) *	2010-12-23	2013-05-24	Italfármaco, S.A.	Compuestos con actividad inhibitoria de factores de crecimiento de fibroblastos.
PT2777699T (pt) *	2012-02-02	2017-07-07	Invesfovea S L	Dietilamina-2,5-di-hidroxibenzenossulfonato para o tratamento de degeneração macular relacionada com a idade
PL404138A1 (pl) *	2013-05-31	2014-12-08	Warszawski Uniwersytet Medyczny	Pochodne kwasu benzoesowego jako inhibitory receptora IL-15Rα
ES2759080T3 (es) *	2015-10-19	2020-05-07	Dobecure S L	Administración local de etamsilato como medicamento

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4115648A (en) *	1974-09-13	1978-09-19	Laboratorios Del Dr. Esteve, S.A.	2,5-Dihydroxy benzene sulfonic acid mono esters
US4513007A (en) *	1983-05-03	1985-04-23	Laboratoires Om Sa	Method for treating heart disease
US4617311A (en) *	1985-05-17	1986-10-14	Eli Lilly And Company	Antiasthmatic method
CH679372A5 (de) *	1989-04-07	1992-02-14	Vet Gerhard Stuker Dr Med
CH682716A5 (de) *	1992-01-13	1993-11-15	Christian Fricker	Benzo-Pyrone und/oder Dobesilat-Calcium enthaltende pharmazeutische Zusammensetzung.
US5981569A (en) *	1992-11-13	1999-11-09	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5374772A (en) *	1992-12-08	1994-12-20	Hoffmann-Laroche Inc.	Substituted benzoic acids, inhibitors of phospholipases A2
US5798356A (en) *	1995-08-07	1998-08-25	Alcon Laboratories, Inc.	Angiostatic compounds
US5977117A (en) *	1996-01-05	1999-11-02	Texas Biotechnology Corporation	Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US6495579B1 (en) *	1996-12-02	2002-12-17	Angiotech Pharmaceuticals, Inc.	Method for treating multiple sclerosis
CA2278421A1 (en) *	1997-02-14	1998-08-20	Kissei Pharmaceutical Co., Ltd.	Drugs inhibiting progress of pterygium and postoperative recurrence of the same
TR200101790T2 (tr) *	1998-12-23	2001-10-22	Idea Ag.	Yayılgan olmayan in vivo topik uygulamalar için geliştirilmiş formül
US20020103141A1 (en) *	1998-12-23	2002-08-01	Mckearn John P.	Antiangiogenic combination therapy for the treatment of cancer
JP2000256259A (ja) *	1999-03-11	2000-09-19	Nippon Zoki Pharmaceut Co Ltd	メイラード反応阻害剤
JP2003501488A (ja) *	1999-06-11	2003-01-14	ネオルックスコーポレイション	骨髄抑制のための高投与量放射性核種錯体
US6921763B2 (en) *	1999-09-17	2005-07-26	Abbott Laboratories	Pyrazolopyrimidines as therapeutic agents
US20020037897A1 (en) *	2000-08-07	2002-03-28	3-Dimensional Pharmaceuticals, Inc.	Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists
JP2002193800A (ja) *	2000-12-22	2002-07-10	Taisho Pharmaceut Co Ltd	Ｖｅｇｆ受容体拮抗剤
US20040092515A1 (en) *	2001-02-28	2004-05-13	Torbjjorn Lundstedt	Diaminoquinazoline esters for use as dihydrofolate reductase inhibitors
EP1452521A4 (de) *	2001-08-17	2007-03-14	Eisai R&D Man Co Ltd	Cyclische verbindung und ppar-agonist
CA2459493C (en) *	2001-09-14	2011-08-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	New pharmaceutical compositions for inhalation
US7163958B2 (en) *	2002-07-03	2007-01-16	Nitromed Inc.	Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
RU2002120366A (ru) *	2002-08-01	2005-02-27	БиоДием Лимитед (AU)	Новые производные имидазолия и фармацевтические композиции на их основе
EP1535915A4 (de) *	2002-09-06	2005-10-05	Takeda Pharmaceutical	Furan- oder thiophenderivat und dessen medizinische verwendung
ES2208123A1 (es) *	2002-11-29	2004-06-01	Laboratorios Del Dr. Esteve, S.A.	Uso de los compuestos 2,5-dihidroxibencenosulfonicos para la fabricacion de un medicamento.
AU2003212672A1 (en) *	2003-01-29	2004-08-23	Dal-Hoon Son	Pharmaceutical composition comprising an extract or compounds isolated from elfvingia applanata for the prevention and the treatment of diabetes and diabetic complications
ES2222831B2 (es) *	2003-07-30	2006-02-16	Laboratorios Del Dr. Esteve, S.A.	Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+.
AU2004263156B2 (en) *	2003-08-07	2009-02-26	Allergan, Inc.	Method for treating cachexia with retinoid ligands
GB0321228D0 (en) *	2003-09-10	2003-10-08	Inpharmatica Ltd	Modulating cell activity
WO2005051356A1 (en) *	2003-10-31	2005-06-09	Elan Pharma International Ltd.	Novel nimesulide compositions
US20050222247A1 (en) *	2003-12-13	2005-10-06	Bayer Healthcare Ag	Chroman derivatives
EP1836160A1 (de) *	2004-12-24	2007-09-26	CTG Pharma S.r.l.	Verbindungen zur behandlung von metabolischem syndrom
EP1676573A1 (de) *	2004-12-30	2006-07-05	Laboratorios Del Dr. Esteve, S.A.	Pharmazeutische Zusammensetzung enthaltend eine 2,5-Dihydroxybenzolsulfonsäure-Verbindung, einen Kalium Kanal Modulator und einen Phosphodiesterase 5 Inhibitor
EP1749820A1 (de) *	2005-07-15	2007-02-07	Laboratorios Del Dr. Esteve, S.A.	Salze von substituierten Pyrazolin Derivaten, ihre Herstellung und Anwendung als Arzneimittel
BRPI0614610A2 (pt) *	2005-08-04	2011-04-05	Novartis Ag	compostos
CN100506804C (zh) *	2006-01-26	2009-07-01	于学敏	羟苯磺酸烷基吡嗪药物及其制备方法和应用
US20070196350A1 (en) *	2006-02-22	2007-08-23	Bartels Stephen P	Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
US8158608B2 (en) *	2006-03-30	2012-04-17	Council Of Scientific And Industrial Research	Bioactive fraction from Zingier officinale and a process for the preparation thereof

2007
- 2007-08-15 WO PCT/EP2007/058444 patent/WO2008020031A1/en not_active Ceased
- 2007-08-15 WO PCT/EP2007/058445 patent/WO2008020032A1/en not_active Ceased
- 2007-08-15 PT PT07788436T patent/PT2056805E/pt unknown
- 2007-08-15 EP EP07802616.8A patent/EP2056804B1/de active Active
- 2007-08-15 WO PCT/EP2007/058447 patent/WO2008020034A1/en not_active Ceased
- 2007-08-15 US US11/839,529 patent/US20080114063A1/en not_active Abandoned
- 2007-08-15 EP EP07788431A patent/EP2054045B1/de active Active
- 2007-08-15 EP EP07788436A patent/EP2056805B1/de active Active
- 2007-08-15 ES ES07802616.8T patent/ES2495965T3/es active Active
- 2007-08-15 AT AT07788431T patent/ATE509621T1/de not_active IP Right Cessation
- 2007-08-15 WO PCT/EP2007/058446 patent/WO2008020033A1/en not_active Ceased
- 2007-08-15 AT AT07788436T patent/ATE510536T1/de not_active IP Right Cessation
- 2007-08-15 US US12/377,837 patent/US9060966B2/en not_active Expired - Fee Related
- 2007-08-15 WO PCT/EP2007/058456 patent/WO2008020042A1/en not_active Ceased
- 2007-08-15 PT PT78026168T patent/PT2056804E/pt unknown
- 2007-08-15 PT PT07788431T patent/PT2054045E/pt unknown
- 2007-08-16 CL CL2007002392A patent/CL2007002392A1/es unknown
- 2007-08-16 CL CL2007002385A patent/CL2007002385A1/es unknown
- 2007-08-16 AR ARP070103643A patent/AR062399A1/es unknown
- 2007-08-16 AR ARP070103634A patent/AR062390A1/es unknown
- 2007-08-16 AR ARP070103637A patent/AR062393A1/es unknown
- 2007-08-16 CL CL2007002387A patent/CL2007002387A1/es unknown
- 2007-08-16 AR ARP070103639A patent/AR062395A1/es unknown
- 2007-08-16 CL CL2007002388A patent/CL2007002388A1/es unknown
- 2007-08-16 AR ARP070103640A patent/AR062396A1/es unknown
- 2007-08-16 CL CL2007002386A patent/CL2007002386A1/es unknown

Also Published As

Publication number	Publication date
WO2008020032A8 (en)	2008-04-17
AR062396A1 (es)	2008-11-05
CL2007002386A1 (es)	2008-01-18
EP2056805B1 (de)	2011-05-25
PT2054045E (pt)	2011-08-31
EP2054045B1 (de)	2011-05-18
AR062393A1 (es)	2008-11-05
PT2056805E (pt)	2011-09-02
EP2054045A1 (de)	2009-05-06
WO2008020033A1 (en)	2008-02-21
ES2495965T3 (es)	2014-09-17
CL2007002392A1 (es)	2008-01-18
CL2007002388A1 (es)	2008-01-18
AR062390A1 (es)	2008-11-05
WO2008020042A1 (en)	2008-02-21
PT2056804E (pt)	2014-07-11
ATE509621T1 (de)	2011-06-15
WO2008020031A1 (en)	2008-02-21
US20080114063A1 (en)	2008-05-15
AR062399A1 (es)	2008-11-05
US20110152222A1 (en)	2011-06-23
WO2008020034A1 (en)	2008-02-21
EP2056805A1 (de)	2009-05-13
WO2008020032A1 (en)	2008-02-21
US9060966B2 (en)	2015-06-23
EP2056804B1 (de)	2013-05-22
EP2056804A1 (de)	2009-05-13
CL2007002387A1 (es)	2008-01-18
CL2007002385A1 (es)	2008-01-18
AR062395A1 (es)	2008-11-05

Publication	Publication Date	Title
ATE510536T1 (de)	2011-06-15	Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
ATE369333T1 (de)	2007-08-15	Sulfonamidderivate zur behandlung von krankheiten
ATE534633T1 (de)	2011-12-15	Indazolderivate zur behandlung von hsp90- induzierten krankheiten
DE602005023172D1 (de)	2010-10-07	Hydantoinderivate zur behandlung von entzündlichen erkrankungen
EP1916964A4 (de)	2015-11-04	Implantate und verfahren zur behebung, ersetzung und behandlung von gelenkkrankheiten
ATE550338T1 (de)	2012-04-15	Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE375977T1 (de)	2007-11-15	Sulfonamidderivate zur behandlung von krankheiten
ATE527241T1 (de)	2011-10-15	Pyridiazinonderivate zur behandlung von tumoren
EP2111223A4 (de)	2012-08-15	Aminderivatverbindungen zur behandlung von augenerkrankungen und -leiden
ATE542823T1 (de)	2012-02-15	4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
EA200802213A1 (ru)	2009-10-30	Способы лечения заболеваний крови
ATE395871T1 (de)	2008-06-15	Marknagel zur behandlung von proximalen oberschenkelknochenbrüchen
EP2010184A4 (de)	2009-12-23	Implantate zur behandlung von dopamin-assoziierten zuständen
ATE476414T1 (de)	2010-08-15	Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
DE602005007717D1 (de)	2008-08-07	Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE602005005810D1 (de)	2008-05-15	Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
EP1732484A4 (de)	2015-01-21	Ophthalmisches implantat zur behandlung von glaukom
ATE448219T1 (de)	2009-11-15	Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen
ATE517085T1 (de)	2011-08-15	Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
ATE447551T1 (de)	2009-11-15	Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE438623T1 (de)	2009-08-15	Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
FI20095600L (fi)	2009-06-09	Koostumus ihosairauksien hoitoa varten
EP1924269A4 (de)	2009-12-16	Vegetationswasser-zusammensetzung zur behandlung von entzündlichen hautkrankheiten
ATE472324T1 (de)	2010-07-15	Isosorbid-mononitrat-derivate zur behandlung von okularer hypertonie
ATE525355T1 (de)	2011-10-15	1-ä(4-äbenzoyl(methyl)aminoü-3- (phenyl)butylüazetidinderivate zur behandlung von gastrointestinalen erkrankungen 1

Legal Events

Date	Code	Title	Description
2011-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties